Table 1.
Patient characteristics
| Overall | Centre #1 | Centre #2 | P-value | |
|---|---|---|---|---|
| Demographics | ||||
| Number of patients | 55 | 22 | 33 | |
| Male | 42 (76) | 16 (73) | 26 (79) | 0.60 |
| Ischaemic cardiomyopathy | 43 (78) | 10 (45) | 33 (100) | <0.01 |
| NYHA (II/III) | 27(49)/28(51) | 10(45)/12(55) | 17(52)/16(48) | 0.66 |
| ECG characteristics | ||||
| Sinus rhythm | 45 (82) | 19 (86) | 26 (79) | 0.48 |
| Atrial fibrillation | 10 (18) | 3 (14) | 7 (21) | 0.48 |
| Heart rate (b.p.m.) | 70 (60–76) | 72 (64–83) | 67 (60–75) | 0.15 |
| QRS duration (ms) | 158 (143–176) | 162 (139–180) | 158 (144–170) | 0.56 |
| LBBB | 51 (93) | 18 (82) | 33 (100) | 0.01 |
| IVCD | 4 (7) | 4 (18) | 0 (0) | 0.03 |
| CMR LV function | ||||
| EF (%) | 25 (21–32) | 25 (20–32) | 26 (21–32) | 0.77 |
| Mass (g) | 157 (136–184) | 156 (140–175) | 160 (131–192) | 0.96 |
| EDV (mL) | 248 (214–314) | 250 (178–320) | 243 (224–310) | 0.68 |
| ESV (mL) | 191 (147–224) | 182 (141–240) | 194 (157–219) | 0.65 |
| Medications | ||||
| ACE inhibitors | 49 (89) | 21 (95) | 28 (85) | 0.22 |
| Diuretics | 48 (87) | 18 (82) | 30 (91) | 0.32 |
| Beta-blockers | 55 (100) | 22 (100) | 33 (100) | — |
Data expressed as median (1st–3rd) quartiles for continuous variables or count (%) for categorical variables. P-value refers to Centre #1 vs. Centre #2, Mann–Whitney U test or Fisher’s exact test when appropriate. Bold values refers to significant p-values (p < 0.05), consistently with the description in the statistical analysis sub-section.
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; IVCD, interventricular conduction disturbance; LBBB, left-bundle branch block; NYHA, New York Heart Association.